Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Diamond-blackfan Anemia
Fanconi Anemia
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2006-02-13

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 43

Registration Number: NCT00290628

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis

Phase 3

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Placebo
Drug: Rituximab
Drug: Mycophenolate mofetil
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Prednisone

First Posted Date: 2006-01-26

Last Posted Date: 2015-01-15

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 144

Registration Number: NCT00282347

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

First Posted Date: 2006-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 200

Registration Number: NCT00281879

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans

Phase 4

Completed

Conditions: Healthy

First Posted Date: 2006-01-25

Last Posted Date: 2008-05-09

Lead Sponsor: Regional Hospital Holstebro

Target Recruit Count: 20

Registration Number: NCT00281710

Locations: 🇩🇰
Department of Medicine, Holstebro Hospital, Holstebro, Denmark

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Phase 1

Terminated

Conditions: MYOPATHY

Interventions: Biological: Hematopoietic stem cell transplantation
Drug: Cyclophosphamide
Drug: Mesna
Drug: ATG(rabbit)
Drug: Methylprednisolone
Drug: G-CSF
Drug: Rituxan

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-06

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT00278564

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients

Phase 4

Completed

Conditions: Graft Rejection
Kidney Failure
Kidney Transplantation

First Posted Date: 2005-12-05

Last Posted Date: 2006-05-19

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 160

Registration Number: NCT00261820

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Phase 2

Completed

Conditions: Fanconi Anemia

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methylprednisolone
Biological: Hematopoietic stem cell transplantation

First Posted Date: 2005-11-24

Last Posted Date: 2021-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 14

Registration Number: NCT00258427

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: methylprednisolone
Drug: temozolomide

First Posted Date: 2005-11-04

Last Posted Date: 2018-09-04

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 16

Registration Number: NCT00248534

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations